Author

A. Azmi

h-index 4 View on Semantic Scholar

We have 3 of 36 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

#protein folding Open access Sep 2026

Second-Generation AOH1996 Analogues with Enhanced Pharmacological Properties for Targeting PCNA

Proliferating Cell Nuclear Antigen (PCNA) plays a critical role in at least 11 distinct cellular pathways. Tumor cells express an acidic isoform of the protein (caPCNA), while nonmalignant cells express only a basic isoform (nmPCNA). We previously identified AOH1996 as a first-in-class, orally bioavailable small mole...

Pouya Haratipour, Maryam Zangi, Long Gu et al. · Journal of Medicinal Chemist... · 0 citations

Aug 2026

XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant pancreatic ductal adenocarcinoma.

KRASG12D-selective and pan-RAS inhibitors have shown promise in pancreatic ductal adenocarcinoma (PDAC), yet adaptive resistance is anticipated to limit durability of response. Exportin 1 (XPO1), a nuclear export protein frequently overexpressed in PDAC, represents a potential vulnerability in KRAS-mutant cancers. We e...

H. Y. Khan, M. Al-Hallak, A. Aboukameel et al. · Cancer Letters · 0 citations

Jul 2026

Abstract A089: ADT-1004: A mechanistically distinct pan-RAS inhibitor with the potential to escape resistance and mitigate on-target toxicities that limit efficacy and safety of other RAS inhibitors

An orally bioavailable prodrug of ADT-1004, ADT-1004, demonstrated favorable tolerability and suppressed tumor growth in orthotopic and patient-derived xenograft models of pancreatic cancer, accompanied by reductions in activated RAS and p-ERK levels (Mol Cancer, 2025).

Junwei Wang, Xi Chen, Bandi D. S. Reddy et al. · Clinical Cancer Research · 0 citations